Ranbaxy launches Soliten to treat urology disorder

Ranbaxy Laboratories today announced the launch of its brand Soliten (Solifenacin) in India for the management of chronic urological disorder.

According to a release issued by Ranbaxy to the BSE today, the product, which will be sold as 5 mg and 10mg tablets, is being introduced for the first time in India.

"Soliten is a new and safer formulation that will provide effective relief from chronic problems of overactive bladder (OAB), which leads to symptoms such as inability to hold urine coupled with urgency and increased frequency to pass urine. The product is documented to have lesser side effects and greater effectiveness," the release added.